Scientific Approach
Pipeline
INBRX-109
INBRX-106
INBRX-105
INBRX-101
Investors
Patients
Partners
Who We Are
Team
Contact Us
News Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Oct 18, 2023
Inhibrx Announces Participation in Upcoming Scientific Conferences
Aug 29, 2023
Inhibrx Announces $200 Million Private Placement Financing
Aug 7, 2023
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
May 8, 2023
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Apr 26, 2023
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
12
»
